间接比较亚裔人群Ⅱ～Ⅲ期胃癌D2根治术后的辅助化疗方案  

Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients

作　　者：江志敏[1] 魏莹[1] 张媛冬[2] 周思维[1] 杨琼[1] 谢德荣[1] 

机构地区：[1]中山大学孙逸仙纪念医院肿瘤科,广州510120 [2]广东省人民医院肿瘤中心

出　　处：《中华胃肠外科杂志》2013年第6期534-537,共4页Chinese Journal of Gastrointestinal Surgery

摘　　要：目的间接比较亚裔人群Ⅱ-Ⅲ期胃癌D2根治术后不同辅助化疗方案的疗效。方法通过数据库电子检索以及手工检索相关文献，选择Ⅱ-Ⅲ期亚裔胃癌D2根治术后辅助化疗与单纯手术治疗比较的前瞻性随机对照临床试验（RCT）。选择总生存率和无病生存率为研究终点指标，通过Bucher校正间接比较法比较不同辅助化疗方案的疗效。结果2项研究纳入分析，1项研究涉及替吉奥（S．1）辅助化疗与单纯手术比较，1项研究涉及XELOX方案（奥沙利铂加卡培他滨）辅助化疗与单纯手术比较。间接比较结果显示，S-1与XELOX方案对总生存率影响的差异无统计学意义（HR=0．94，95％CI：0．62～1．44，P=0．79）。S-1较XELOX方案复发风险略有增加．但差异无统计学意义（HR=1．11，95％CI：0．80～1．53，P=0．54）。结论亚裔人群胃癌D2根治术后，S-1单药与XELOX方案辅助化疗疗效近似。Objective To compare efficacy of different adjuvant chemotherapy regimens for stage II- III gastric cancer after D2 gastrectomy in Asian patients. Methods Associated literatures were searched through electronic databases and hand-searching. Prospective randomized clinical trials（RCTs） comparing adjuvant chemotherapy after D2 gastrectomy with surgery alone were included in the study. Overall survival and disease-free survival were chosen as the endpoints. Relative hazard was analyzed by Bucher adjusted indirect comparison. Results Two RCTs were selected, including comparison between S-1 versus surgery alone and comparison between XELOX versus surgery alone. There was no statistical difference in overall survival between the two regimens （HR=0.94, 95%CI：0.62-1.44, P=0.79）. The recurrence risk of S-1 was slightly higher as compared to XELOX, but no statistical difference was found （HR=I.ll, 95%CI：0.80-1.53, P=0.54）. Conclusion The adjuvant chemotherapy with S-1 is similar to XELOX for stage II- III gastric cancer after D2 gastrectomy in Asian patients.

关 键 词：胃肿瘤 辅助化疗 治疗效果 间接比较 

分 类 号：R735[医药卫生—肿瘤]